Pharsight

Keppra patents expiration

KEPPRA's oppositions filed in EPO

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8802142 UCB INC Pharmaceutical compositions comprising levetiracetam and process for their preparation
Jun, 2031

(6 years from now)

US8802142

(Pediatric)

UCB INC Pharmaceutical compositions comprising levetiracetam and process for their preparation
Dec, 2031

(7 years from now)

Keppra is owned by Ucb Inc.

Keppra contains Levetiracetam.

Keppra has a total of 2 drug patents out of which 0 drug patents have expired.

Keppra was authorised for market use on 30 November, 1999.

Keppra is available in tablet;oral dosage forms.

The generics of Keppra are possible to be released after 07 December, 2031.

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Dec 16, 2014
Pediatric Exclusivity(PED) Jun 16, 2015

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using LEVETIRACETAM ingredient

Market Authorisation Date:

30 November, 1999

Treatment:

NA

Dosage:

TABLET;ORAL

How can I launch a generic of KEPPRA before its drug patent expiration?

More Information on Dosage

KEPPRA family patents

Family Patents